Abstract
The genetic bases of mosaic pigmentation disorders have increasingly been identified, but these conditions remain poorly characterised, and their pathophysiology is unclear. Here, we report in four unrelated patients that a recurrent postzygotic mutation in GNA13 is responsible for a recognizable syndrome with hypomelanosis of Ito associated with developmental anomalies. GNA13 encodes Gα13, a subunit of αβγ heterotrimeric G proteins coupled to specific transmembrane receptors known as G-protein coupled receptors. In-depth functional investigations revealed that this R200K mutation provides a gain of function to Gα13. Mechanistically, we show that this variant hyperactivates the RHOA/ROCK signalling pathway that consequently increases actin polymerisation and myosin light chains phosphorylation, and promotes melanocytes rounding. Our results also indicate that R200K Gα13 hyperactivates the YAP signalling pathway. All these changes appear to affect cell migration and adhesion but not the proliferation. Our results suggest that hypopigmentation can result from a defect in melanosome transfer to keratinocytes due to cell shape alterations. These findings highlight the interaction between heterotrimeric G proteins and the RHOA pathway, and their role in melanocyte function.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Agence Nationale de la Recherche (ANR; RIDES 2019, Cytoskinflam 2023), Inserm, Inserm Transfert (COPOC 2023), and Universite Paris Cite (UPC). R.E.M. was supported by a postdoctoral fellowship from ANR. A.I. is supported by an international PhD fellowship from UPC and a European Society for Immunodeficiencies fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individuals were recruited and phenotyped by dermatologists and geneticists collaborators of the M.U.S.T.A.R.D. (Mosaic Undiagnosed Skin Traits And Related Disorders) cohort whose ethical approval was given by the Ethics Committee of the Federation Hospitalo-Universitaire TRANSLAD (Medecine TRANSLAtionnelle dans les anomalies du Developpement) from the Centre Hospitalier Universitaire Dijon Bourgogne, as part of a French collaborative effort to identify genes involved in skin mosaic syndromes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Deceased
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
